Sugi Predict

Sugi Predict / Compounds / SCHEMBL3990482

SCHEMBL3990482

SCHEMBL3990482

CC1(C)OC(=O)C(Cc2ccc(O)cc2)O1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLA P06280 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ CAPN1 P07384 1/20 0.42
▸ LMNA P02545 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ GAA P10253 7/20 0.37
▸ MGAM O43451 2/20 0.37
▸ SI P14410 2/20 0.37
▸ MGAM2 Q2M2H8 2/20 0.37
▸ ESR1 P03372 4/20 0.35
▸ MAPT P10636 2/20 0.35
▸ GLS O94925 1/20 0.34
▸ SIRT1 Q96EB6 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ CYP26A1 O43174 1/20 0.33
▸ ESR2 Q92731 2/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ POLB P06746 2/20 0.32
▸ RECQL P46063 1/20 0.32
▸ GSK3B P49841 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5385235 1.00 GLA (0.44) GLANPSR1CAPN1LMNASMN1; SMN2
SCHEMBL3524748 0.83 GLA (0.43) GLANPSR1
SCHEMBL3524746 0.83 GLA (0.43) GLANPSR1
SCHEMBL5380212 0.78 MEN1 (0.50) GLANPSR1LMNAPPARG
SCHEMBL3994040 0.78 MEN1 (0.50) GLANPSR1LMNAPPARG
SCHEMBL13804959 0.77 POLB (0.48) GLANPSR1LMNASMN1; SMN2GAA
SCHEMBL24163244 0.73 CAPN1 (0.47) CAPN1GAAESR1CYP26A1ESR2
SCHEMBL3585383 0.71 LMNA (0.37) LMNASMN1; SMN2GAAESR1MAPT
SCHEMBL21726165 0.71 GLS (0.40) GLANPSR1GLS
SCHEMBL21726166 0.71 GLS (0.40) GLANPSR1GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544812-B2 For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus ELI LILLY AND COMPANY (US) 2009-06-09 — — US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 — — US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 — — US disclosed
US-20050020652-A1 Peroxisome proliferator activated receptor agonists ELI LILLY AND COMPANY 2005-01-27 — — US disclosed
EP-1453811-A2 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2004-09-08 — — EP disclosed
WO-2003048130-A2 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020652-A1 Peroxisome proliferator activated receptor agonists PPARA, PPARD, PPARG GLA 2767/4885NPSR1 712/4885CAPN1 3507/4885
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA GLA 3793/4885NPSR1 684/4885CAPN1 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.